Mary Francis Rooney

Dr. Mary Francis Rooney

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMary Francis Rooney
Mary Francis Rooney
EHEmmeline W Hill
Emmeline W Hill
VKVincent P Kelly
Vincent P Kelly
RPRichard Kevin Porter
Richard Kevin Porter
Thoroughbred horses are finely-tuned athletes with a high aerobic capacity relative to skeletal muscle mass, attributable to centuries of genetic selection for speed and stamina. Polymorphisms in the myostatin gene (MSTN), a pronounced inhibitor of skeletal muscle growth, have been shown to almost singularly account for gene-based race distance aptitude in racehorses. In Thoroughbreds, two MSTN polymorphisms, a single nucleotide variation in the first intron (SNP g.66493737C>T) and a non-coding transposable element within the promoter region (a 227 bp SINE insertion) are of particular interest. Until now, it has not been clear which of these variants affect skeletal muscle phenotypes or whether both can impact racing performance. In a large cohort of Thoroughbreds, we observed a complete concordance between the SNP and the SINE insertion. By means of in vitro assays in C2C12 myoblasts, we isolated the SNP variant from the SINE polymorphism and showed the latter is exclusively responsible for adversely affecting transcription initiation and gene expression thereby limiting myostatin protein production. Mapping the MSTN transcription start site in horse skeletal muscle likewise revealed anomalous transcription initiation in the presence of the SINE insertion. Our data provides mechanistic evidence that the SINE insertion uniquely accounts for the MSTN “speed gene” effect on race distance aptitude in the Thoroughbred horse.

30 November 2017 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MRMary Francis Rooney
Mary Francis Rooney
RPRichard Kevin Porter
Richard Kevin Porter
LKLisa M Katz
Lisa M Katz
EHEmmeline Hill
Emmeline Hill
Variation in the myostatin (MSTN) gene has been reported to be associated with race distance, body composition and skeletal muscle fibre composition in the horse. The aim of the present study was to test the hypothesis that MSTN variation influences mitochondrial phenotypes in equine skeletal muscle. Mitochondrial abundance and skeletal muscle fibre types were measured in whole muscle biopsies from the gluteus medius of n = 82 untrained (21 ± 3 months) Thoroughbred horses. Skeletal muscle fibre type proportions were significantly (p < 0.01) different among the three MSTN genotypes and mitochondrial content was significantly (p < 0.01) lower in the combined presence of the C-allele of SNP g.66493737C>T (C) and the SINE insertion 227 bp polymorphism (I). Evaluation of mitochondrial complex activities indicated higher combined mitochondrial complex I+III and II+III activities in the presence of the C-allele / I allele (p ≤ 0.05). The restoration of complex I+III and complex II+III activities following addition of exogenous coenzyme Q1 (ubiquinone1) (CoQ1) in vitro in the TT/NN (homozygous T allele/homozygous no insertion) cohort indicated decreased coenzyme Q in these animals. In addition, decreased gene expression in two coenzyme Q (CoQ) biosynthesis pathway genes (COQ4, p ≤ 0.05; ADCK3, p ≤ 0.01) in the TT/NN horses was observed. This study has identified several mitochondrial phenotypes associated with MSTN genotype in untrained Thoroughbred horses and in addition, our findings suggest that nutritional supplementation with CoQ may aid to restore coenzyme Q activity in TT/NN horses.

3 January 2019 in Equine Veterinary Journal
Verified
Journal Article
Closed access
PDF file
EHEmmeline Hill
Emmeline Hill
BMB. A. McGivney
B. A. McGivney
MRMary Francis Rooney
Mary Francis Rooney
Lisa Michelle KatzLisa Michelle Katz
Lisa Michelle Katz
APAndrew C Parnell
Andrew C Parnell
DMD. E. MacHugh
D. E. MacHugh

8 November 2023 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
JNJohn Noone
John Noone
MRMary Francis Rooney
Mary Francis Rooney
MKMarilena Karavyraki
Marilena Karavyraki
AYAndrew Yates
Andrew Yates
SOSaoirse O'Sullivan
Saoirse O'Sullivan
RPRichard Kevin Porter
Richard Kevin Porter
Cachexia syndrome, leading to reduced skeletal muscle and fat mass, is highly prevalent in cancer patients, resulting in further negative implications for these patients. To date, there is no approved therapy for cachexia syndrome. The objective of this study was to establish an in vitro model of cancer cachexia in mature human skeletal muscle myotubes, with the intention of exploiting the cell model to assess potential cachexia therapeutics, specifically cannabinoid related drugs. Having cultured and differentiated primary human muscle myoblasts to mature myotubes, we successfully established two cancer cachexia models using conditioned media (CM) from human colon adenocarcinoma (SW480) and from non-small-cell lung carcinoma (H1299) cultured cells. The cancer-CM-induced extensive myotube degeneration, demonstrated by a significant reduction in mature myotube diameter, which progressed over the period studied. Myotube degeneration is a characteristic feature of cancer cachexia and was used in this study as an index of cachexia. Expression of cannabinoid 1 and 2 receptors (CB1R and CB2R) was confirmed in the mature human skeletal muscle myotubes. Subsequently, the effect of cannabinoid compounds on this myotube degeneration were assessed. Tetrahydrocannabinol (THC), a partial CB1R/CB2R agonist, and JWH133, a selective CB2R agonist, proved efficacious in protecting mature human myotubes from the deleterious effects of both (SW480 and H1299) cancer cachexia conditions. ART27.13, a full, peripherally selective CB1R/CB2R agonist, currently being trialled in cancer cachexia (IRAS ID 278450, REC 20/NE/0198), was also significantly protective against myotube degeneration in both (SW480 and H1299) cancer cachexia conditions. Furthermore, the addition of the CB2R antagonist AM630, but not the CB1R antagonist Rimonabant, abolished the protective effect of ART27.13. In short, we have established a convenient and robust in vitro model of cancer-induced human skeletal muscle cachexia. The data obtained using the model demonstrate the therapeutic potential of ART27.13 in cancer-induced cachexia prevention and provides evidence indicating that this effect is via CB2R, and not CB1R.

5 December 2022 in Biochemistry and Biophysics Reports
Verified
Journal Article
Open access
MRMary Francis Rooney
Mary Francis Rooney
NNNuno G.B. Neto
Nuno G.B. Neto
MMMichael G. Monaghan
Michael G. Monaghan
EHEmmeline Hill
Emmeline Hill
RPRichard K. Porter
Richard K. Porter
Thoroughbred racehorse performance is largely influenced by a major quantitative trait locus at the myostatin (MSTN) gene which determines aptitude for certain race distances due to a promoter region insertion mutation influencing functional phenotypes in skeletal muscle. To develop an in vitro system for functional experiments we established three novel equine skeletal muscle cell lines reflecting the variation in phenotype associated with MSTN genotype (CC/II, CT/IN and TT/NN for SNP g.66493737C > T/SINE insertion 227 bp polymorphism). Primary equine skeletal muscle myoblasts, isolated from Thoroughbred horse gluteus medius, were conditionally immortalised and evaluated to determine whether cell phenotype and metabolic function were comparable to functional characteristics previously reported for ex vivo skeletal muscle isolated from Thoroughbred horses with each genotype. Primary myoblasts conditionally immortalised with the temperature sensitive SV40TtsA58 lentivirus vector successfully proliferated and could revert to their primary cell phenotype and differentiate into multinucleated myotubes. Skeletal muscle fibre type, MSTN gene expression, mitochondrial abundance, and mitochondrial function of the three MSTN genotype cell lines, were consistent with equivalent characterisation of ex vivo skeletal muscle samples with these genotypes. Furthermore, addition of coenzyme Q10 (CoQ10) to the cell lines improved mitochondrial function, an observation consistent with ex vivo skeletal muscle samples with these genotypes following supplementation with CoQ10 in the diet. The observation that the phenotypic characteristics and metabolic function of the cells lines are equivalent to ex vivo skeletal muscle indicates that this in vitro system will enable efficient and cost-effective analyses of equine skeletal muscle for a range of different applications including understanding metabolic function, testing of nutritional supplements, drug test development and gene doping test development. In the multi-billion-euro international Thoroughbred horse industry research advances in the biological function of skeletal muscle are likely to have considerable impact. Furthermore, this novel genotype-specific system may be adapted and applied to human biomedicine to improve understanding of the effects of myostatin in human physiology and medicine.

13 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
BMBrian Maloney
Brian Maloney
MKMartyna Kubisztal
Martyna Kubisztal
ZGZiqian Ge
Ziqian Ge
YLYin Lu
Yin Lu
LSLisa Strotmann
Lisa Strotmann
RPRichard Kevin Porter
Richard Kevin Porter
Oral squamous cell carcinoma (OSCC) is major cause of human cancer. The enzyme, nicotinamide N-methyltransferase (NNMT) is overexpressed in a variety of human cancers including OSCC. Our laboratory identified two small molecule inhibitors of NNMT (AG-670 and AO-022) based on a pharmacophore of the in silico nicotinamide binding site. These inhibitors were demonstrated to inhibit the isolated NNMT enzyme with EC50 values in the micromolar range. Using an oral squamous cancer cell line as a model, it was demonstrated that NNMT is expressed in SCC-4 cells, but not MCF 7 cells, and that the inhibitors were cytotoxic to SCC-4 cells (IC50 values in the micromolar range). In an endeavour to investigate the mechanism behind their lethality, sub-lethal doses of the inhibitors were demonstrated to inhibit in situ mitochondrial oxygen consumption in SCC-4 cells but not in MCF 7 cells. It was further demonstrated that the NNMT inhibitors did not directly inhibit mitochondrial electron transport chain activity. Thus, we can deduce that the NNMT inhibitors effect mitochondrial activity indirectly via NNMT. We conclude that NNMT is a potential drug target for oral cancer.